An updated patent review of AKT inhibitors (2020-present)

IntroductionProtein kinase B (Akt), an essential protein in the PI3K/Akt/mTOR signaling pathway, plays a crucial role in tumor progression. Over the past two years, different types of Akt modulators have continued to emerge in the patent literature.Areas coveredThis review focuses on the patent literature covering small molecule inhibitors, peptides, PROTACs, and antisense nucleic acids targetingAkt from 2020 to present. Also, we discuss the outcomes of several clinical trials, combination strategies for different mechanisms, and the application of Akt regulators in other non-oncology indications.Our search for relevant information was conducted using various databases, including the European Patent Office, SciFinder, andPubMed, from 01.2020 to 04.2023.Expert opinionIn recent years, some combination therapeutic strategies involvingAkt inhibitors have shown promising clinical outcomes. Future research can be directed toward developing new applications of Akt inhibitors, which may have implications for other diseases beyond cancer. New attempts suggest that targeting allosteric sites may be a potential solution to the problem of isoform selectivity.Furthermore, directly knocking out Akt protein by using the degraderssuggests a promising direction for future development.

Automated summary

In this review, the patent literature covering various types of Akt modulators from 2020 to present is discussed. The outcomes of clinical trials, combination strategies, and non-oncology applications of Akt regulators are also explored. The search for relevant information was conducted using multiple databases, including the European Patent Office, SciFinder, and PubMed, from January 2020 to April 2023.